iBio earnings release, August 28, 2026

iBio, Inc. (IBIO) · Form 8-K, Item 2.02 · Filed · SEC filing

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress.

“Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. “Additional highlights came from our IBIO-610 program, where we presented preclinical data supporting its potential for fat-selective weight loss, complementing with current GLP-1 therapies by increasing fat loss while preserving lean mass, and to reduce weight regain following GLP-1 discontinuation. We are excited to build on this progress as we continue advancing our pipeline and working toward our mission of delivering transformative treatments to patients.”

Progress on Obesity and Cardiometabolic Pipeline

​

Corporate Developments

Financing and Capital Resources

Leadership Updates

“In this last fiscal year, we paired significant scientific progress with disciplined financial execution, substantially strengthening iBio’s balance sheet as we advance our pipeline toward and into clinical development,” said Felipe Druan, Chief Financial Officer. “Our successful financings, which extended our cash runway into fiscal year 2028, together with the addition of highly experienced leaders to our Board and management team, provide a strong foundation to execute on our clinical programs and translate continued scientific progress into meaningful value for patients and shareholders.”

Financial Results:

Revenues for the fiscal year ended June 30, 2026, were approximately $0.1 million, a decrease of $0.3 million over the $0.4 million in revenue for the fiscal year 2025.

​

Research and Development (“R&D”) expenses for the fiscal year ended June 30, 2026, and June 30, 2025, were approximately $19.6 million and $8.3 million, respectively, an increase of approximately $11.3 million. The increase in R&D expenses is mainly due to increased spending of approximately $8.4 million on consultants and outside services supporting our R&D efforts, including NHP studies and CMC activities, for iBio’s IBIO-610 and IBIO-600 programs and other preclinical pipeline assets, and a $2.5 million development milestone.

General and Administrative expenses for the fiscal year ended June 30, 2026, and June 30, 2025, were approximately $10.6 million and $10.7 million, respectively, a decrease of approximately $0.1 million.

Impairment of Indefinite-Lived Intangible Assets for the fiscal year ended June 30, 2026, was approximately $5.0 million and was attributable to the impairment of our indefinite-lived intangible asset, IBIO-101. No impairments of indefinite-lived intangible assets were recorded for the fiscal year ended June 30, 2025. iBio held cash and cash equivalents and investments in debt securities of approximately $88.0 million as of June 30, 2026.

About iBio, Inc. iBio

(Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

For more information, visit www.ibioinc.com or follow us on LinkedIn.

Financial statements

Income Statement

(In Thousands, except per share amounts)

Year Ended – June 30, – 2026Year Ended – June 30, – 2025
Revenue100400
Operating expenses:Research and development19,6438,312
Operating expenses:General and administrative10,59510,690
Operating expenses:Impairment of indefinite-lived intangible asset5,003
Operating expenses:Total operating expenses35,24119,002
Operating expenses:Operating loss-35,141-18,602
Other income (expense):Interest income2,150437
Other income (expense):Interest expense-53-212
Other income (expense):Total other income2,097225
Other income (expense):Net loss before income taxes-33,044-18,377
Other income (expense):Net loss-33,044-18,377
Comprehensive loss:Net loss-33,044-18,377
Comprehensive loss:Other comprehensive loss - unrealized loss on debt securities-45
Comprehensive loss:Comprehensive loss-33,089-18,377
Comprehensive loss:Loss per common share - basic and diluted-0.32-1.75
Comprehensive loss:Weighted-average common shares outstanding - basic and diluted - see Note 17104,06010,499

Balance Sheet

June 30, 2026 — (In Thousands, except share and per share amounts)

June 30, 2026June 30, 2025
Current assets:Cash and cash equivalents56,3958,582
Current assets:Investments in debt securities (adjusted cost $31,689 and $0 as of June 30, 2026 and June 30, 2025, respectively - see Note 6)31,644
Current assets:Subscription receivable105
Current assets:Promissory note receivable and accrued interest1,104
Current assets:Prepaid expenses and other current assets3,0781,034
Current assets:Total Current Assets92,2219,721
Current assets:Restricted cash228210
Current assets:Promissory note receivable and accrued interest1,098
Current assets:Finance lease right-of-use assets, net of accumulated amortization68
Current assets:Operating lease right-of-use asset, net of accumulated amortization1,6672,051
Current assets:Fixed assets, net of accumulated depreciation3,0863,163
Current assets:Intangible assets, net of accumulated amortization1,8256,848
Current assets:Prepaid expenses - noncurrent73
Current assets:Security deposits1026
Current assets:Total Assets99,11023,185
Current liabilities:Accounts payable4,4232,188
Current liabilities:Accrued expenses5,6261,345
Current liabilities:Finance lease obligations53
Current liabilities:Operating lease obligation - current portion546490
Current liabilities:Equipment financing payable - current portion64
Current liabilities:Term promissory note766
Current liabilities:Contract liabilities1,1501,200
Current liabilities:Total Current Liabilities11,7456,106
Current liabilities:Operating lease obligation - net of current portion1,6522,199
Current liabilities:Total Liabilities13,3978,305
Stockholders’ EquityCommon Stock - $0.001 par value; 275,000,000 shares authorized; 55,698,561 and 19,349,201 shares issued and outstanding as of June 30, 2026 and June 30, 2025, respectively5619
Stockholders’ EquityAdditional paid-in capital450,970347,085
Stockholders’ EquityAccumulated other comprehensive loss-45
Stockholders’ EquityAccumulated deficit-365,268-332,224
Stockholders’ EquityTotal Stockholders’ Equity85,71314,880
Stockholders’ EquityTotal Liabilities and Stockholders’ Equity99,11023,185
Full release

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding

IBIO-600 potentially being a best-in-class, long-acting anti-myostatin monoclonal antibody to preserve muscle and improve body composition; IBIO-610’s potential for fat-selective weight loss, complementing GLP-1 therapy by increasing fat loss while preserving lean mass, and reducing weight regain following GLP-1 discontinuation; iBio continuing to advance its pipeline and working toward its mission of delivering transformative treatments to patients; the potential for infrequent dosing of IBIO-610, iBio’s long-acting Activin E antibody; preclinical studies of IBIO-610 supporting its potential as a differentiated treatment for obesity and related cardiometabolic diseases; the four planned cohorts of the IBIO-600 Phase 1 clinical trial; the potential to move IBIO-600 into multiple ascending dose portion of the clinical trial; the potential of IBIO-600 to preserve muscle and improve body

​ composition, including as a potential complement to GLP-1-based therapies; the potential of IBIO-800 to preserve and increase muscle and address cardiopulmonary disease; the assumed exercise of all of the warrants sold in the August 2025 public offering in full for cash;

Dr. Carr leading the company’s global clinical strategy, medical affairs, and regulatory initiatives; the company advancing its obesity and cardiometabolic pipeline toward and into clinical development;... (truncated)y experienced leaders to iBio’s Board and management team, together with its successful financings, providing a strong foundation to continue translating scientific progress into meaningful clinical and corporate value; iBio’s differentiated pipeline delivering sustained therapeutic effects and addressing significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2026. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Corporate Contact: iBio, Inc.

Investor Relations ir@ibioinc.com

Media Contacts:

Ignacio Guerrero-Ros, Ph.D., or David Schull

Russo Partners, LLC

Ignacio.guerrero-ros@russopartnersllc.com

David.schull@russopartnersllc.com

(858) 717-2310 or (646) 942-5604

​

​ iBio, Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

(In Thousands, except per share amounts)

​

​

​ iBio, Inc. and Subsidiaries

Consolidated Balance Sheets

(In Thousands, except share and per share amounts)

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · iBio earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.